Skip to main
DRIO

DarioHealth (DRIO) Stock Forecast & Price Target

DarioHealth (DRIO) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

DarioHealth is a virtual chronic care company with a unique business model that combines hardware, software, and personalized coaching to drive behavior change and improve patient outcomes. The recent acquisition of Twill and transition to the enterprise market positions DarioHealth for success, with potential for revenue growth, increased EBITDA, and positive cash flow by mid 2027. However, risks in the HCIT space, such as government program cuts and price competition, could impact spending and customer retention. Overall, DarioHealth's strong value proposition and potential for growth make it a promising investment opportunity.

Bears say

DarioHealth is experiencing a challenging demand environment, potentially due to the company's focus on cost management. While the company has made improvements in its cost management and has a strong pipeline, there is limited visibility for growth in its B2B2C and strategic partnerships channels. There is also risk of churn and capturing sufficient lives. However, there is potential for upside if the company can cross-sell its products and services to legacy Twill customers and reach breakeven sooner than expected through lower OpEx.

DarioHealth (DRIO) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DarioHealth and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DarioHealth (DRIO) Forecast

Analysts have given DarioHealth (DRIO) a Buy based on their latest research and market trends.

According to 2 analysts, DarioHealth (DRIO) has a Buy consensus rating as of Jun 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DarioHealth (DRIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.